Clinical Trial

APA (Adapted Physical Activity) for Patients With Advanced Melanoma

Study acronym: APA-M
Recruiting
View on ClinicalTrials.gov →
Summary
APA (adapted physical activity) for patients with advanced melanoma APA (adapted physical activity) for patients with advanced melanoma undergoing treatment: evaluation of a personalized program at the hospital Melanoma is a malignant tumor developed from melanocytes. It accounts for approximately 4% of all incident cancers and 1.2% of cancer deaths, regardless of sex. Since 2011, the advent of new therapies (targeted therapies and immunotherapies) has revolutionized the management of advanced-stage melanoma (unresectable stage III or stage IV). These treatments have led to a significant improvement in the prognosis of metastatic melanoma, with a 5-year overall survival rate of 34% for targeted therapies, 44% for monotherapy with immunotherapy, and 52% for the combination of nivolumab + ipilimumab. Due to the improvement in survival rates, advanced melanoma has become a chronic disease affecting all ages. It is therefore essential to maintain the quality of life for these patients.
Trial Details
NCT Number NCT07031830
Lead Sponsor University Hospital, Rouen
Conditions Melanoma of Skin
Enrollment 50 participants
Start Date 2024-11-18
Primary Completion 2028-11-18 (estimated)
Study Completion 2029-01-02 (estimated)
Updated on ClinicalTrials.gov 2025-06-22